
- | Portage Biotech
The evolving immuno-oncology landscape

- | Ring Therapeutics
Harnessing The Human Virome For The Next Generation Of Gene Therapy Vectors
Ring’s research team has uncovered and characterized the world’s largest collection of commensal anelloviruses and is harnessing those best suited for specifically targeting a wide array of diseases with significant unmet needs. The unique biology of anelloviruses may indeed provide a foundation for an unparalleled new gene therapy platform and the resulting new class of genetic medicines.

- | SalioGen
Gene-coding startup brings in $115M, eyes expansion
At just 10 months out of stealth, gene-editing startup SalioGen Therapeutics has lassoed a $115 million round with plans to double its team, build out its drug pipeline and move to a new, expanded facility.

- | Aptinyx
Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level
As 2022 begins, Aptinyx is laying the groundwork to transition to a late-stage clinical, and one day commercial, company. At the same time, its senior leadership also is transitioning into new roles. Andy Kidd, M.D., takes on the role of CEO after stints as Aptinyx’s president and chief operating officer, and before that, chief commercial officer. Norbert Riedel, Ph.D., who led the company for years as CEO, is stepping back from day-to-day execution into a new role as executive chairman.

- | Pyxis Oncology
Will Pyxis Oncology Be Pfizer’s Fourth Billion-Dollar Spinout?
It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not. “There were a number of programs that had great clinical data, but unfortunately, did not have a development path within Pfizer,” she elaborates.
- | Alto Neuroscience
Mental health startup Cerebral teams with Alto Neuroscience to bring ‘precision psychiatry’ to patients’ homes
Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes.

- | MeiraGTx
A Biotech Unveils Its New Gene Control Technology
When she helped start MeiraGTx Holdings in 2015, CEO Zandy Forbes wanted to find a way to precisely control the output of genes implanted in people to fix genetic disorders. In an analyst meeting Wednesday, MeiraGTx unveiled that technology.

- | Scynexis
Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis
Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.